AVANIR (AVNR) Higher As Phase III Trial Meets Efficacy Endpoint
Tweet Send to a Friend
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) is seeing upside action today after the company announced detailed results from the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


